Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Osteogenic growth peptide 10-14 L

Drug Profile

Osteogenic growth peptide 10-14 L

Alternative Names: OGP 10-14 L

Latest Information Update: 18 Mar 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abiogen Pharma
  • Class Peptides
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis

Highest Development Phases

  • Discontinued Myelofibrosis; Stem cell mobilisation

Most Recent Events

  • 11 May 2006 Phase-I/II clinical trials in Stem cell mobilisation in Italy (IV-injection)
  • 11 May 2006 No development reported - Phase-I for Myelofibrosis in Italy (IV-injection)
  • 06 Oct 2003 Osteogenic growth peptide 10-14 L has received Orphan Drug Status for Myelofibrosis in Italy
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top